Has bevacizumab (avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? systematic review answering this question

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 6, Issue 1, 2012, Pages 70-77

  Koukourakis, Georgios V ^a  

^a UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Angiogenesis; Avastin; Bevacizumab; Brain gliomas; Colorectal cancer; Metastasis

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CARMUSTINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; TEMOZOLOMIDE; VASCULOTROPIN A; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER METASTASIS; LUNG EMBOLISM; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; REVIEW; STOMACH PERFORATION; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; GLIOMA; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PATENTS AS TOPIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855826070     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221312798889284     Document Type: Review

References (55)

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007; 12(1): 20-37.
2. Holick CN, Giovannucci EL, Rosner B, Stampfer MJ, Michaud DS. Prospective study of cigarette smoking and adult glioma: Dosage, duration, and latency. Neuro Oncol 2007; 9(3): 326-34.
3. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al. Long-term survival with glioblastoma multiforme. Brain 2007; 130(Pt 10): 2596-606.
4. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, De-Monte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95(2): 190-8.
5. Bloom HJ. Combined modality therapy for intracranial tumours. Cancer 1975; 35(1): 111-20.
6. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987-96.
7. Folkman J. Tumour angiogenesis: Therapeutic implications. N Engl J Med 1971; 285(21): 1182-6.
8. Ries LAG, Melbert D. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http: //seer.cancergov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.(Accessed on: May 8, 2011).
9. Cancer. net. Colorectal Cancer-Overview. Available at http: //www.cancer.net/patient/Cancer+Types/Colorectal+Cancer. In. 9. (Accessed on: May 8, 2011).
10. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-8.
11. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6): 669-76.
12. Dvorak HF. Discovery of vascular permeability factor (VPF). Exp Cell Res 2006; 312(5): 522-6.
13. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Manseau EJ, et al. VEGF-A induces angiogenesis, arteriogenesis, lymphangiogenesis, and vascular malformations. Cold Spring Harb Symp Quant Biol 2002; 67: 227-37.
14. Tanaka K, Yamaguchi S, Sawano A, Shibuya M. Characterization of the extracellular domain in vascular endothelial growth factor receptor-1 (Flt-1 tyrosine kinase). Jpn J Cancer Res 1997; 88(9): 867-76.
15. Wang L, Zeng H, Wang P, Soker S, Mukhopadhyay D. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem 2003; 278(49): 48848-60.
16. Zafirellis K, Agrogiannis G, Zachaki A, Gravani K, Karameris A, Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer. J Surg Res 2008; 147(1): 99-107.
17. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavourable prognostic factor in human colorectal carcinoma. Cancer 1996; 78(2): 226-31.
18. Melnyk O, Shuman MA, Kim KJ. Vascular endothelial growth factor promotes tumour dissemination by a mechanism distinct from its effect on primary tumour growth. Cancer Res 1996; 56(4): 921-4.
19. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362(6423): 841-4.
20. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumourigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95(4): 1789-97.
21. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumour regression without overt toxicity. J Clin Invest 2000; 105(8): R15-24.
22. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2(4): 306-14.
23. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. A perivascular niche for brain tumour stem cells. Cancer Cell 2007; 11(1): 69-82.
24. Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanised monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data. J Clin Oncol 2001; 19(3): 851-6.
25. Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, et al. A phase I/II dose escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30(5 Suppl 16): 117-24.
26. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomised trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349(5): 427-34.
27. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19(3): 843-50.
28. Jain RK. Normalizing tumour vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7(9): 987-9.
29. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
30. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, et al. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 2005; 23: 3502-8.
31. Avastin prescribing information. Available at http: //www.gene.com/gene/ products/information/pdf/avastinprescribing. pdf. (Accessed on: May 8, 2011).
32. Fuchs CS, Marshal J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomised, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study. J Clin Oncol 2007; 25: 4779-86.
33. Fuchs CS, Marshall J, Barrueco J. Randomised, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 2008; 26: 689-90.
34. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomised phase III study. J Clin Oncol 2008; 26: 2013-9.
35. Köhne CH, De Greve J, Hartmann JT, Lang I, Vergauwe P, Becker K, et al. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008; 19: 920-6.
36. Ziras N, Polyzos A, Kakolyris S. CAPIRI (capecitabine, irinotecan) + bevacizumab vs FOLFIRI (folinic acid, 5 fluorouracil, irinotecan) + bevacizumab for the treatment of patients with metastatic colorectal cancer (mCRC): Interim analysis for safety of a randomised phase III trial. J Clin Oncol 2008; 26(suppl 20): 15008.
37. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, et al. Bevacizumab in combination with Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 12(20): 1539-44.
38. Grothey A, Sugrue M, Hedrick E. Association between exposure to Bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). J Clin Oncol 2007; 25(suppl 18): 4036.
39. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, Di Bartolomeo M, et al. Safety and efficacy of first line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009; 20(11): 1842-7.
40. Ali SA, McHayleh WM, Ahmad A, Sehgal R, Braffet M, Rahman M, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: A series of 13 cases. J Neurosurg 2008; 109(2): 268-72.
41. Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, et al. Antiangiogenic therapy using bevacizumab in recurrent highgrade glioma: Impact on local control and patient survival. J Neurosurg 2009; 110(1): 173-80.
42. Poulsen HS, Grunnet K, Sorensen M, Olsen P, Hasselbalch B, Nelausen K, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. Acta Oncol 2009; 48(1): 52-8.
43. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009; 91(3): 329-36.
44. Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumours, an evaluation of efficacy and safety. J Neurooncol 2008; 89(1): 113-8.
45. Nghiemphu PL, Liu W, Lee Y, Than T, Graham C, Lai A, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: A single-institution experience. Neurology 2009; 72(14): 1217-22.
46. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70(10): 779-87.
47. nd, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25(30): 4722-9.
48. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 2007; 9(1): 29-38.
49. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, et al. Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008; 10(2): 162-70.
50. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27(28): 4733-40.
51. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumour progression in recurrent glioblastoma. J Clin Oncol 2009; 27(5): 740-5.
52. Shachar, Y., Chen, T., Farkas, C., Marx, B., Johnson, D., Farkas, L. Enhanced method for delivering Bevacizumab into a brain tumour using an implanted magnetic breather pump. US20110092960 (2011).
53. Ljubimova, J.Y., Ljubimov, A.V., Black, K.L. Monoclonal antibodies for inhibition of Laminin-8 expression to inhibit human gliomas. US20090263379 (2009).
54. Ljubimova, J.Y., Ljubimov, A.V. Black, K.L. Antisense inhibition of laminin-8 expression to inhibit human gliomas. US7547511 (2009).
55. Martell, R.A., Karlin, D. A. Use of picoplatin and bevacizumab to treat colorectal cancer. US20110052580 (2011).